Research output per year
Research output per year
Search results
-
2017
A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.
Rovithi, M., Labots, M., Richard, E., Honeywell, RJ., Ten Tije, A. J., Ruijter, R., Skardhamar, M., Peters, G. J., Voortman, J. & Verheul, H. M. W., 20 May 2017, In: Journal of clinical oncology. 35Research output: Contribution to journal › Meeting Abstract › Academic
-
2015
A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types
Rovithi, M., Voortman, J., Luik, A. M., Ruijter, R., de Haas, R., Honeywell, R., Labots, M., Poel, D., Peters, G. J., Griffioen, A. W. & Verheul, H. M. W., 20 May 2015, In: Journal of clinical oncology. 33, 15Research output: Contribution to journal › Meeting Abstract › Academic
-
2014
High-dose, intermittent sunitinib as an alternative treatment strategy
Rovithi, M., de Haas, R. R., Honeywell, R. J., Voortman, J., Griffioen, A. W., Labots, M., Luik, A. M., Peters, G. J., Broxterman, H. J. & Verheul, H. M. W., 1 Oct 2014, In: Cancer research. 74, 19Research output: Contribution to journal › Meeting Abstract › Academic
Open Access -
2008
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and peripheral blood mononuclear cells
Voortman, J., Ceresa, C., Giovannetti, E., Laan, A. C., Honeywell, R., Giaccone, G. & Peters, G. J., 2008, In: Annals of Oncology. 19, p. 34-34Research output: Contribution to journal › Meeting Abstract › Academic